Loading quotes...
Forecast
| Buy |
1 |
| Hold |
1 |
| Sell |
0 |
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | 2023 | YoY |
|---|---|---|
| Revenue | 0 | - |
| Gross profit | -226.15k | 88.33% |
| Net profit | -7.81m | 48.73% |
| EBITDA | -7.7m | 64.34% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €185.39k |
Number of shares | 1.14m |
52-week high/low | €0.57 - €0.00464 |
| Dividends | No |
Beta | 6.09 |
P/E ratio | -0.02 |
PEG ratio | 0.00 |
P/B ratio | 0.04 |
P/S ratio | 0.00 |
Company profile
Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of immunomodulatory therapies for the treatment of pain from osteoarthritis in the United States. Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial for the treatment of osteoarthritis of the knee; AP-017, an intravenous ampion treatment that is in Phase II clinical trial to treat adult COVID-19 patients requiring oxygen supplementation; AP-019, an Inhaled Ampion treatment, which is in Phase II clinical trial for the treatment of Adults with Respiratory Distress Due to COVID-19; and AP-018 that is in Phase I clinical trial to treat patients with prolonged respiratory symptoms due to COVID-19. The company is headquartered in Englewood, Colorado.
| Name | Ampio Pharmaceuticals |
| CEO | Michael A. Martino |
| Headquarters | Englewood,
co USA |
| Website | |
| Sector | Materials |
| Industry | Chemicals |
| IPO | 31/03/2010 |
| Employees | 6 |
Ticker symbols
| Exchange | Symbol |
|---|---|
AMEX | AMPE |
Düsseldorf | APH.DU |
Frankfurt | APH.F |
München | APH.MU |
